ST Pharm Joins EURO TIDES 2025 to Expand Global Client Engagement

Held in Basel, Switzerland from November 11

ST Pharm announced on November 14 that it participated in EURO TIDES 2025, held in Basel, Switzerland from November 11 to 13 (local time), to promote its technological capabilities to global clients.

Jung Hyukjun, Head of Business Division at ST Pharm, is presenting at 'EURO TIDES 2025' held in Basel, Switzerland. ST Pharm

EURO TIDES is the largest RNA-focused conference in Europe, bringing together experts in nucleic acid (oligonucleotide)-based therapeutics and peptide therapeutics. This year’s event covered four key topics: minimizing regulatory approval risks through regulatory strategies, the latest trends in obesity and metabolic disease therapeutics, innovative technologies for antibody-oligonucleotide conjugates (AOCs), and case studies on purification and processing in line with the expansion of the peptide market.

ST Pharm highlighted its strengths to global clients attending EURO TIDES through major sessions. Jung Hyukjun, Executive Director, delivered a spotlight presentation titled "Choosing the Right CDMO: How a Korea-based Partner ST Pharm can Accelerate Your API to Market," focusing on strategies to accelerate entry into the API market through Korea-based ST Pharm.

Additionally, over the three-day event, the company showcased two poster presentations: ▲ "Hybrid Enzymatic Process Development for Next-Generation Oligonucleotide Manufacturing" and ▲ "STLNP: A Novel Lipid Nanoparticle System for Innovative xRNA Therapeutic Delivery."

CEO Sung Mujae, Head of Business Division Choi Seokwoo, Head of Business Division Jung Hyukjun, Head of Bio Research Center Kim Sungwon, and other key staff members attended the event, seeking to attract new clients and secure new project contracts.

A representative from ST Pharm stated, "By participating in EURO TIDES 2025, we actively promoted our technology and business capabilities to major European pharmaceutical and biotech companies," adding, "We will continue striving to play a leading role in the global RNA CDMO sector."

This content was produced with the assistance of AI translation services.